Impaired insulin sensitivity and hypertension are risk factors for atherosclerosis, which in turn leads to a variety of cardiovascular diseases. In both conditions, the risks of morbidity and mortality appear to be further increased. Impaired insulin sensitivity is also a precursor for diabetes. The renin-angiotensin-aldosterone system (RAAS) is implicated in the development of both hypertension and insulin resistance. Antihypertensive agents that act by blocking the RAAS, such as angiotensin-con-verting enzyme (ACE) inhibitors, may improve insulin sensitivity and therefore prevent the deleterious consequences of insulin resistance, including type 2 diabetes. ACE inhibitors appear to improve insulin sensitivity in patients with hypertension and insulin resistance, including diabetes. This review assesses the literature surrounding the use of the ACE inhibitor perindopril in patients with hypertension and varying degrees of insulin resistance, including the effects of perindopril in preventing the development of diabetes and subsequent cardiovascular morbidity and mortality.
1. Julius S, Majahalme S, Palatini P.Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens2001;14(suppl):310–16.
2.
2. Fogari R, Mugellini A, Zoppi A. et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens2002;15:316–20.
3.
3. Dzau V.The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens2005;23(suppl 1):9–17.
4.
4. McFarlane SI, Kumar A, Sowers JR.Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol2003;91(suppl):30H–37H.
5.
5. Sjöholm A, Nyström T.Endothelial inflammation in insulin resistance. Lancet2005;365:610–12.
6.
6. Morganti A.Should a diuretic always be the first choice in patients with essential hypertension? The case for no. J Am Soc Nephrol2005;16(suppl 1):S70–S73.
7.
7. Sharma AM, Janke J, Gorzelniak K. et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension2002;40:609–11.
8.
8. Hsueh WA, Law RE.Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med1998;105(suppl):4–14.
9.
9. Tikellis C, Wookey PJ, Candido R. et al. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes2004;53:989–97.
10.
10. Ingelfinger JR, Solomon CG.Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance - is there still hope?N Engl J Med2006;355:1608–10.
11.
11. Opie LH, Schall R.Old antihypertensives and new diabetes. J Hypertens2004;22:1453–8.
12.
12. Andersen NH, Poulsen SH, Poulsen PL. et al. Left ventricular dysfunction in hypertensive patients with type 2 diabetes mellitus. Diabet Med2005;22:1218–25.
13.
13. Salmasi AM, Dancy M.Glucose intolerance: the hidden danger in hypertensives!. IntAngiol2005;24:207–14.
14.
14. Burnier M, Zanchi A.Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens2006;24:11–25.
15.
15. Brewster UC, Perazella MA.The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med2004;116:263–72.
16.
16. Cordonnier DJ, Pinel N, Barro C. et al. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. J Am Soc Nephrol1999;10:1253–63.
17.
17. McLennan SV, Kelly DJ, Cox AJ. et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia2002;45:268–75.
18.
18. Erensoy N, Yilmazer S, Öztürk M et al. Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes. Acta Histochemica2004;106:279–87.
19.
19. Hsieh T-J, Fustier P, Wei C-C et al. Reactive oxygen species blockade and action of insulin on expression of angiotensinogen gene in proximal tubular cells. J Endocrinol2004;183:535–50.
20.
20. Adachi H, Hirai Y, Tsuruta M. et al. Is insulin resistance or diabetes mellitus associated with stroke? An 18-year follow-up study. Diabetes Res Clin Pract2001;51:215–23.
23. Patel V, Rassam SMB, Chen HC. et al. Effect of angiotensin-converting enzyme inhibition with perindopril and beta-blockade with atenolol on retinal blood flow in hypertensive diabetic subjects. Metabolism1998;47(suppl 1):28–33.
24.
24. Lithell HO, Pollare, Berne C.Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol1990;15(suppl 5):S46–S52.
25.
25. Bak JF, Gerdes LU, Sorensen NS, Pedersen O.Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med1992;92(4B):69S–72S.
26.
26. Jandrain B, Herbaut C, Depoorter J-C, Vd Voorde K.Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension. Am J Med1992;92(suppl 4B):91–4.
27.
27. Messerli FH, Grossman E, Leonetti G.Antihypertensive therapy and new-onset diabetes. J Hypertens2004;22:1845–7.
28.
28. Jacob S, Rett K, Henriksen EJ.Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of β-blocking agents?Am J Hypertens1998;11:1258–65.
29.
29. Verdecchia P, Reboldi G, Angeli F. et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension2004;43:963–9.
30.
30. Taylor EN, Hu FB, Curhan GC.Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care2006;29:1065–70.
31.
31. Oksa A, Gajdos M, Fedelesova V. et al. Effects of angiotensin-converting enzyme inhibitors on glucose and lipid metabolism in essential hypertension. J Cardiovasc Pharmacol1994;23:79–86.
32.
32. Gillespie EL, White CM, Kardas M. et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care2005;28:2261–6.
33.
33. Dagenais GR, Pogue U, Fox K, Simoons ML, Yusuf S.Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet2006;368:581–8.
34.
34. The DREAM Trial Investigators.Effect of ramipril on the incidence of diabetes. N Engl J Med2006;355:1551–62.
35.
35. Jandeleit-Dahm KAM, Tikellis C, Reid CM et al. Why blockade of the renin-angiotensin system reduced the incidence of new-onset diabetes. J Hypertens2005;23:463–73.
36.
36. Furuhashi M, Ura N, Higashiura K. et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension2003;42:76–81.
37.
37. Carlsson PO, Berne C, Jansson L.Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia1998;41:127–33.
38.
38. Tahmasebi M, Puddefoot JR, Inwang ER. et al. The tissue renin-angiotensin system in human pancreas. J Endocrinol1999;161:317–22.
39.
39. Miyata T, Taguchi T, Uehara M. et al. Bradykinin potentiates insulin-stimulated glucose uptake and enhances insulin signal through the bradykinin B2 receptor in dog skeletal muscle and rat L6 myoblasts. Eur J Endocrinol1998;138:344–52.
40.
40. Dietze GJ, Wcklmayr M, Rett K. et al. Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes1996;45(suppl 1):S110–S114.
41.
41. Rett K, Wicklmayr M, Dietze GJ. et al. Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes1996;45(suppl 1):S66–S69.
42.
42. Campbell DJ, Kladis A, Duncan AM.Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension1994;23:439–49.
43.
43. Fogari R, Zoppi A, Lazzari P. et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovas Pharmacol1998;32:616–20.
44.
44. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med2000;342:145–53.
45.
45. Hansson L, Lindholm LH, Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet1999;353:611–16.
46.
46. ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA2002;288:2981–97.
47.
47. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomised controlled trial. Lancet2005;366:895–906.
48.
48. Brichard S, Ketelslegers JM, Lambert AE.Renal function, glycaemic control and perindopril in diabetic patients. Arch Mal Coeur1989;82:57–61.
49.
49. Derosa G, Cicero AFG, Ciccarelli L, Fogari R.A randomized, double-blind, controlled, parallel-group comparison of perindopril and can-desartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther2003;25:2006–21.
50.
50. Jinxiu L, Daguang C, Kegui W. et al. The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension (article in Chinese). Natl Med J China1998;78:200–02.
51.
51. Uchida K, Azukizawa S, Kigoshi T. et al. Effects of perindopril on glucose and lipid metabolism in patients with mild-to-moderate essential hypertension and glucose intolerance. Clin Ther1994;16:466–70.
52.
52. Stumpe KO, Overlack A.A new trial of the efficacy, tolerability, and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS). Am J Cardiol1993;71:32E–37E.
53.
53. Gupta A.Determinants of new-onset diabetes among hypertensive patients randomised in the ASCOT-BPLA trial [abstract]. Presented at the joint meeting of the World Congress of Cardiology/European Society of Cardiology; 2006 Sept 2-6; Barcelona, Spain.
54.
54. Sever P.ASCOT subgroup analysis and recent update [oral presentation]. Presented at the 41st Annual Meeting of the European Association for the Study of Diabetes, 2005 Sept 10-15; Athens, Greece. Oral presentation available from URL: http://www.easd-lectures.org/athens/index.php?menu=thumbs&id=87 [Accessed 2006Dec 7]
55.
55. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B.The diabetogenic potential of thiazide-type diuretic and beta-block-er combinations in patients with hypertension. J Hypertens2005;23:1777–81.
56.
56. Fressinaud P, Berrut G, Gallois H.Antihypertensive activity and acceptability based upon clinical and laboratory parameters of perindopril: chief results in 23, 460 mild to moderate hypertension patients treated for 6 months in general practice (French). Ann Cardiol Angéiol1993;42:51–9.
57.
57. Suraniti S, Berrut G, Marre M, Fressinaud P.Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol1993;71:28E–31E.
58.
58. Julius S, Cohn JN, Neutel J. et al. Antihypertensive utility of perindopril in a large, general practice-based clinical trial. J Clin Hypertens2004;6:10–17.
59.
59. Yasuda, G, Hasegawa K, Kuji T et al. Perindopril effects on ambulatory blood pressure: relation to sympathetic nervous activity in subjects with diabetic nephropathy. Am J Hypertens2004;17:14–20.
60.
60. Daly CA, Fox KM, Remme WJ. et al. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J2005;26:1369–78.
61.
61. Ito A, Egashira K, Narishige T. et al. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J2002;66:811–15.
62.
62. Cooper ME, Cao Z, Rumble JR. et al. Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. Metabolism1998;47(suppl 1):24–7.
63.
63. Girerd X, Giannattasio C, Moulin C. et al. Regression of radial artery wall hypertrophy and improvement of carotid artery compliance after long term antihypertensive treatment: the PERICLES study. J Am Coll Cardiol1998;31:1064–73.
64.
64. Tropeano A-I, Boutouyrie P, Pannier B et al. Brachial pressure-independent reduction in carotid stiffness after long term angiotensin converting enzyme inhibition in diabetic hypertensives. Hypertension2006;48:1–7.
65.
65. Boutouyrie P, Tropeano AI, Asmar R. et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension2002;39:10–15.
66.
66. Laurent S, Boutouyrie P, Asmar R. et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension2001;37:1236–41.
67.
67. Thybo NK, Stephens N, Cooper A. et al. Efficacy of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension1995;25(4 Pt 1):474–81.
68.
68. Marketou ME, Zacharis EA, Papadaki E. et al. Angiotensin converting enzyme inhibitors improves myocardial adrenergic innervation disturbances in normotensive patients with diabetes type II. J Am Coll Cardiol2005;45(3 suppl A):261A.
69.
69. Manolis AJ, Iraklianou S, Pittaras A. et al. Arterial compliance changes in diabetic normotensive patients after angiotensin-converting enzyme inhibition therapy. Am J Hypertens2005;18:18–22.
70.
70. Zhou M, Zhong H-J, Wu X-Y.Changes of ultrastructure and function of the aortic endothelium in streptozocin-diabetic rats and effect of perindopril. Bull Hunan Med Univ2001;26:41–4.
71.
71. Liu S-K, Chen X, You J-L, Zhou M.Protective effect of perindopril on dysfunction of endothelium-dependent relaxation in diabetic rats. Bull Hunan Med Univ2000;25:122–4.
72.
72. Toblli JE, Cao G, DeRosa G. et al. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens2004;17:172–80.
73.
73. Rumble JR, Komers R, Cooper ME.Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. J Hypertens1996;14:601–07.
74.
74. Melbourne Diabetic Nephropathy Study Group.Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ1991;302:210–16.
75.
75. Hermans MP, Brichard SM, Colin I. et al. Long-term reduction of microalbuminuria after 3 years of angiotensin-converting enzyme inhibition of perindopril in hypertensive insulin-treated diabetic patients. Am J Med1992;92(suppl 4B):102–07.
76.
76. Langham RG, Kelly DJ, Thomson NM. et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia2002;45:1572–6.
77.
77. Nankervis A, Nicholls K, Kilmartin G. et al. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism1998;47(suppl 1):12–15.
78.
78. White KE, Pinel N, Cordonnier DJ. et al. Does ACE inhibition slow progression of glomerulopathy in patients with type 2 diabetes mellitus?Diabetic Med2001;18:933–6.
79.
79. Langham RG, Kelly DJ, Gow RM. et al. Transforming growth factor-β in human diabetic nephropathy. Diabetes Care2006;29:2670–5.
80.
80. Hoy WE, Wang Z, Baker PRA, Kelly AM.Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int2005;98(suppl):76–82.
81.
81. Kvetny J, Gregersen G, Smith Pedersen R.Randomized, placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. Q J Med2001;94:89–94.
82.
82. Jerums G, Allen TJ, Campbell DJ. et al. Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis2001;37:890–9.
83.
83. Jerums G, Allen TJ, Campbell DJ. et al. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with type 2 diabetes and microalbuminuria. Diabetic Med2004;21:1192–9.
84.
84. Duggan KA, Hodge G, Makarious MM, Charlesworth JA.Renoprotective differences between perindopril and enalapril in the diabetic hypertensive rat do not reflect glomerular angiotensin-converting enzyme activity. Clinical Science1998;94:511–16.
85.
85. Kelly DJ, Stein-Oakley J, Zhang Y. et al. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2)27 rats: attenuation with renin-angiotensin blockade. Nephrology2004;9:7–13.
86.
86. Yan L, Yang R, Cheng H. et al. Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozocin-induced diabetic rats. Chinese Med J1998;111:306–08.
87.
87. Velasquez MT, Striffler JS, Abraham A. et al. Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. Hypertension1997;30:1232–7.
88.
88. PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033–41.
89.
89. Fox KM, EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet2003;362:782–8.
90.
90. Chalmers J, Perkovic V, Joshi R. et al. ADVANCE: breaking new ground in type 2 diabetes. J Hypertens Suppl2006;24:S22–S28.
